Merck Beats Estimates with Strong Keytruda Sales

Merck's quarterly sales exceeded expectations, driven by strong demand for its top-selling cancer treatment Keytruda. The company reported revenue of $16.61 billion in the second quarter, a 5% increase from the same period last year and above analysts' estimates.

The success of Keytruda was attributed to the popularity of its subcutaneous formulation, Keytruda QLEX, which contributed significantly to the sales growth. According to Merck's chief financial officer Caroline Litchfield, the company is on track to achieve 30-40% adoption of QLEX by the end of 2027.

Merck also raised its full-year revenue forecast, expecting $66.3 billion to $67.3 billion in sales for 2026. This increase reflects the company's confidence in Keytruda's performance and its ability to maintain market share in the vaccines segment.